iRay Group

iRay Group Debt

The Debt of iRay Group (688301.SS) as of Oct 15, 2026 is 3.72 B CNY. In the previous year, Debt was 3.54 B CNY — a change of 4.91% (higher).

Debt

3.72 BCNY

YoY

4.91%

Last updated:

In 2025, iRay Group's total debt was 3.72 B CNY, a 4.91% change from the 3.54 B CNY total debt recorded in the previous year.

The iRay Group Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
9.91 M CNY
Jan 1, 2019
58.07 M CNY
Jan 1, 2020
73.68 M CNY
Jan 1, 2021
59.65 M CNY
Jan 1, 2022
1.43 B CNY
Jan 1, 2023
2.10 B CNY
Jan 1, 2024
3.54 B CNY
Jan 1, 2025
3.72 B CNY
The iRay Group Debt history
YEARDebtYoY
3.72 BCNY+4.91%
3.54 BCNY+68.87%
2.10 BCNY+46.37%
1.43 BCNY+2,302.39%
59.65 MCNY-19.05%
73.68 MCNY+26.89%
58.07 MCNY+485.75%
9.91 MCNY+111.56%
4.69 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iRay Group Stock analysis

What does iRay Group do? iRay Group, operating under the ticker symbol 688301.SS and identified by ISIN CNE1000042V8, is a prominent entity within the Chinese healthcare sector. Headquartered in Shanghai, the company has established itself as a significant player in the medical technology industry, specifically focusing on the development and manufacturing of advanced digital imaging solutions. The organization went public on September 18, 2020, marking a pivotal moment in its corporate history and allowing it to expand its operational capabilities on a broader scale. As of the latest available data, iRay Group employs a workforce of 1,237 full-time employees, reflecting its substantial operational footprint and commitment to human capital in driving technological innovation. The core business of the company revolves around the research, development, production, and sale of digital X-ray detectors, which are critical components in modern medical diagnostic equipment. These detectors are engineered to provide high-resolution imaging, enabling healthcare professionals to make accurate and timely diagnoses. The product portfolio of iRay Group is diverse and tailored to meet various clinical and industrial needs. Key product lines include the universal radio frequency series, which offers versatile imaging solutions for general diagnostic purposes. Additionally, the company manufactures specialized breast series detectors designed specifically for mammography, ensuring high sensitivity and image clarity for early detection of breast abnormalities. The radiotherapy series further expands the company's reach into therapeutic applications, providing essential imaging support for radiation treatment planning and monitoring. Beyond the medical sector, the technology developed by iRay Group finds application in industrial non-destructive testing and security inspection fields. This diversification highlights the robustness of their detector technology, which can be adapted for inspecting materials integrity in manufacturing or screening for security threats. The company maintains a comprehensive distribution network that serves both the domestic market within China and international markets overseas. This global reach underscores the competitive quality of their products and the company's strategic focus on expanding its presence in the worldwide healthcare and industrial technology sectors. By leveraging its expertise in digital X-ray technology, iRay Group continues to contribute to advancements in medical diagnostics and industrial safety, positioning itself as a key innovator in the health care industry. iRay Group is one of the most popular companies on Eulerpool.

Debt Details

Understanding iRay Group's Debt Structure

iRay Group's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing iRay Group's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to iRay Group’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in iRay Group’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about iRay Group stock

Debt of iRay Group is 3.72 B CNY in 2025.

Debt of iRay Group changed from 3.54 B CNY to 3.72 B CNY, representing a 4.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt iRay Group since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's iRay Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — iRay Group

All Key Metrics — iRay Group